Innocenti Federico
Eshelman School of Pharmacy, Center for Pharmacogenomics and Individualized Therapy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
F1000Res. 2017 Mar 29;6. doi: 10.12688/f1000research.10475.1. eCollection 2017.
This article describes the clinical relevance of toxicity of therapies administered to patients with cancer, putting the patient, rather than disease, at the center of the evaluation of safety of anti-cancer therapy. Hence, the implications of adverse events are described from the patient perspective, focusing on the impact of patient safety on quality of life and efficacy of treatment. Issues revolving around other types of safety, such as financial toxicity, are also discussed. The role played by genetics in the assessment of a patient's risk of adverse events is also discussed, both in relation to the potential of genomic research and in the context of current tools of fruition in clinical care.
本文描述了给予癌症患者的治疗方法的毒性的临床相关性，将患者而非疾病置于抗癌治疗安全性评估的中心。因此，从患者角度描述了不良事件的影响，重点关注患者安全对生活质量和治疗效果的影响。还讨论了围绕其他类型安全性的问题，如经济毒性。此外，还讨论了遗传学在评估患者不良事件风险中所起的作用，既涉及基因组研究的潜力，也涉及临床护理中当前可用工具的背景。
